IDEAYA Biosciences, Inc., a synthetic precision medicine oncology company focused on lethality, is focused on the discovery and development of targeted therapies for selected patient populations using molecular diagnostics. The company is headquartered in South San Francisco, California. Show more

5000 SHORELINE COURT, SOUTH SAN FRANCISCO, CA, UNITED STATES, 94080, South San Francisco, CA, 94080, USA

https://www.ideayabio.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

3.855B

52 Wk Range

$23.23 - $42.68

Previous Close

$40.10

Open

$39.85

Volume

587,802

Day Range

$38.90 - $40.20

Enterprise Value

3.231B

Cash

272.6M

Avg Qtr Burn

-163.4M

Insider Ownership

2.19%

Institutional Own.

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Darovasertib (IDE196) + Crizotinib (PKC/ALK Inhibitor) Details Adjuvant Therapy For Primary Uveal Melanoma	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Darovasertib (IDE196) + crizotinib Details Solid tumor/s, Metastatic uveal melanoma, Cancer	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Darovasertib Details Cancer, Ocular melanoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Darovasertib (IDE196) + crizotinib Details Solid tumor/s, Metastatic uveal melanoma, Cancer, Cutaneous Melanoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Darovasertib Details Uveal melanoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IDE397 (MAT2A) Details Solid tumor/s, Cancer, Non-small cell lung carcinoma, Bladder cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IDE397 (MAT2A) + Trodelvy Details MTAP-Deletion Urothelial Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IDE892 Details MTAP-Deletion Solid Tumors	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IDE892 + IDE397 (PRMT5/MAT2A Inhibition) Details MTAP-Deletion Solid Tumors	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IDE161 +/- KEYTRUDA® (pembrolizumab) Details Solid tumor/s, Cancer, ER+/HER2- breast cancer, Ovarian cancer, Endometrial cancer	Phase 1b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IDE849 + IDE161 (PARG-ADC Combination) Details DLL3-Upregulated Solid Tumors (SCLC, NETs, NECs, Melanoma)	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IDE849 + IDE161 (TOP1-PARG Combination) Details DLL3-Upregulated Solid Tumors	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IDE034 (B7H3/PTK7 TOP1 ADC) Details Multiple solid tumors expressing B7H3 and PTK7	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IDE849 (SHR-4849) Details Solid tumors	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IDE574 (KAT6/7 Inhibitor) Details Solid Tumors	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IDE892 + RG6505 (Pan-RAS Inhibitor) Details MTAP-Deletion Pancreatic Ductal Adenocarcinoma	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IDE275 (GSK959) Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GSK101 (IDE705) + niraparib Details Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IDE397 (MAT2A) +/- AMG 193 Details Solid tumor/s, Cancer, Non-small cell lung carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.